



Response document for MHRA public consultation on the
proposal to make Dovonex Psoriasis Ointment available in Pharmacies

ANNEX 1

Ref: ARM95

Your details

Name:

[REDACTED]

Position (if applicable):

Organisation (if applicable):

Email:

1. Do you consider that Dovonex Psoriasis Ointment should be available as a Pharmacy medicine?

Yes No Not sure

Please provide any comments or evidence to support your response:

I have been using Dovonex for many years for the treatment of mild psoriasis on my limbs. To be able to access it in a pharmacy without having to request a repeat prescription would be beneficial to me as pharmacies are accessible at times when a doctor's surgery is not. As I live in Wales then I can currently obtain Dovonex for free under prescription however I would not be averse to paying for it within the pharmacy setting as it provide greater flexibility in access.

2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Dovonex Psoriasis Ointment?

None

3. Do you have any other comments on the reclassification?

None

4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Yes Partially* No

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gsi.gov.uk) to arrive by **20 April 2017**. Contributions received after that date cannot be included in the exercise.